- Mr. Ajer was most recently Chief Commercial Officer at BioMarin -

- Ajer先生最近担任BioMarin的首席商务官 -

WALTHAM, Mass.--(BUSINESS WIRE)--

马萨诸塞州沃尔瑟姆--（BUSINESS WIRE）--

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors.

Viridian Therapeutics, Inc.（纳斯达克股票代码：VRDN）是一家专注于发现和开发针对严重和罕见疾病的潜在一流药物的生物制药公司，今天宣布任命Jeff Ajer为其董事会成员。

Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, including leading commercial planning for late-stage pipeline programs, product marketing, reimbursement, and sales operations. He most recently served as the Executive Vice President and Chief Commercial Officer (CCO) at BioMarin Pharmaceutical, where he joined in 2005 as one of the first sales and marketing employees and subsequently held roles of increasing responsibility that helped to establish BioMarin’s commercial infrastructure and global footprint.

Ajer先生在罕见病和专科药物的商业化方面拥有超过25年的经验，包括领导晚期研发管线项目的商业规划、产品营销、报销以及销售运营。他最近曾担任BioMarin制药公司的执行副总裁兼首席商务官（CCO），于2005年作为公司首批销售和市场员工之一加入，并在此后承担了越来越多的责任，帮助建立了BioMarin的商业基础设施和全球业务布局。

Mr. Ajer had direct responsibility for the launch of 5 brands during his time as CCO. Prior to BioMarin, Mr. Ajer served as Vice President, Global Transplant Operations at Genzyme Corporation and held positions in sales, marketing, and operations at SangStat Medical Corporation and ICN Pharmaceuticals.

阿杰尔先生在担任首席商务官期间直接负责五个品牌的上市。在加入BioMarin之前，阿杰尔先生曾任健赞公司副总裁兼全球移植业务负责人，并曾在SangStat医药公司和ICN制药公司担任销售、市场和运营等职位。

He received his B.S. degree in chemistry and M.B.A. from the University of California, Irvine..

他获得了加州大学欧文分校的化学学士学位和工商管理硕士学位。

“We are pleased to welcome Jeff to our Board of Directors at an exciting time for Viridian as we advance veligrotug, which we believe has a clinically differentiated profile, to BLA submission and, if approved, commercial launch,” said Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics.

“我们很高兴在 Viridian 的激动人心的时刻欢迎 Jeff 加入我们的董事会，因为我们正在推进具有临床差异化特点的 veligrotug，向 BLA 递交申请，并且如果获得批准，将进行商业发布，” Viridian Therapeutics 总裁兼首席执行官 Steve Mahoney 表示。

“Jeff’s extensive experience and expertise in commercial strategy and execution is a great addition to our Board as we continue to develop Viridian’s potential best-in-class assets across our thyroid eye disease and FcRn portfolios.”.

“杰夫在商业战略和执行方面的丰富经验与专业技能，对我们董事会来说是一个很好的补充，因为我们正在继续开发Viridian在甲状腺眼病和FcRn产品组合中的潜在最佳资产。”

Notice of Inducement Grants

诱导赠款通知

Today, Viridian announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 220,750 shares of the company’s common stock to 14 new employees (the “Inducement Grants”) on April 1, 2025 (the “Grant Date”).

今天，Viridian 宣布公司董事会薪酬委员会的大多数独立董事批准，在 2025 年 4 月 1 日（“授予日”）向 14 名新员工授予购买公司总计 220,750 股普通股的非限制性股票期权（“入职授予”）。

The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4)..

诱导性赠款是在公司修订和重述的2016年股权激励计划（“计划”）之外授予的，但仍受该计划条款和条件的约束。这些诱导性赠款是根据纳斯达克上市规则5635(c)(4)的规定，作为这些个人与Viridian建立雇佣关系的实质性诱因而授予的。

The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to each employee’s continued employment with Viridian through the applicable vesting dates..

诱导性授予的每股行权价格等于授予日Viridian普通股的收盘价。诱导性授予将在四年期间内归属，其中25%的股份将在员工入职一周年时归属，此后剩余股份将在36个月内按等额月分期归属，但需以每位员工在相应归属日期前持续为Viridian工作为条件。

About Viridian Therapeutics

关于Viridian Therapeutics

Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas..

Viridian是一家生物制药公司，专注于为患有严重和罕见疾病的患者发现、开发和商业化潜在的同类最佳药物。Viridian在抗体发现和蛋白质工程方面的专长使得其能够在已验证的药物靶点和成熟的商业疾病领域中开发差异化的治疗候选药物。

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED.

Viridian正在临床推进多种候选药物，用于治疗甲状腺眼病（TED）患者。该公司正在进行veligrotug（VRDN-001）的关键项目，包括两项全球3期临床试验（THRIVE和THRIVE-2），以评估其在活动性和慢性TED患者中的疗效与安全性。

Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED..

THRIVE 和 THRIVE-2 均报告了积极的初步数据，达到了各自研究的所有主要和次要终点。Viridian 还正在推进 VRDN-003 作为一种潜在的最佳皮下治疗方案，用于治疗 TED，包括两项正在进行的全球 III 期关键临床试验 REVEAL-1 和 REVEAL-2，以评估 VRDN-003 在活动性和慢性 TED 患者中的有效性和安全性。

In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

除了其TED产品组合外，Viridian还在推进一种新型的新生儿Fc受体（FcRn）抑制剂组合，包括VRDN-006和VRDN-008，这些药物有潜力在多种自身免疫疾病中开发。

Viridian is based in Waltham, Massachusetts. For more information, please visit

Viridian 总部位于马萨诸塞州沃尔瑟姆。欲了解更多信息，请访问

www.viridiantherapeutics.com

www.viridiantherapeutics.com

. Follow Viridian on

关注Viridian

LinkedIn

领英

and

和

X

X

.

。

Forward-Looking Statement

前瞻性声明

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “will,” “could”, “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements.

本新闻稿可能包含1995年《私人证券诉讼改革法》及其他联邦证券法所指的前瞻性陈述和信息。使用“可能”、“将”、“可能”、“应该”、“预期”、“打算”、“计划”、“预期”、“相信”、“估计”、“预测”、“项目”、“寻求”、“努力”、“潜在”、“继续”等词语或这些词语的否定形式或其他类似表达，可用于识别前瞻性陈述。

The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation the risks described from time to time in the “Risk Factors” section of our filings with the Securities and Exchange Commission (SEC), including those described in our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as applicable, and supplemented from time to time by our Current Reports on Form 8-K.

本新闻稿中包含的明示或暗示的前瞻性陈述仅为预测，且受多种风险、不确定性和假设的影响，包括但不限于我们在向证券交易委员会（SEC）提交的文件中“风险因素”部分不时描述的风险，特别是我们最近的年度报告（Form 10-K）或季度报告（Form 10-Q）中所述的风险（如适用），并由我们不时提交的当前报告（Form 8-K）进行补充。

In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events.

鉴于这些风险、不确定性和假设，本新闻稿中讨论的前瞻性事件和情况可能不会发生，实际结果可能与前瞻性声明中预期或暗示的结果有重大不利差异。您不应将前瞻性声明视为对未来事件的预测。

Although Viridian believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Any forward-looking statement speaks only as of the date on which it was made.

尽管Viridian认为前瞻性陈述中反映的预期是合理的，但它不能保证前瞻性陈述中反映的未来结果、活动水平、表现或事件和情况将会实现或发生。任何前瞻性陈述仅代表其作出之日的情况。

Neither Viridian, nor its affiliates, advisors, or repres.

既不是翠绿，也不是其附属公司、顾问或代表。

Source: Viridian Therapeutics, Inc.

来源：Viridian Therapeutics, Inc.

IR@viridiantherapeutics.com

IR@viridiantherapeutics.com

Source: Viridian Therapeutics, Inc.

来源：Viridian Therapeutics, Inc.